Lupus Nephritis Market to Advance at a CAGR of 8.5% During the Forecast Period (2025-2034) | DelveInsight
The total lupus nephritis market size is anticipated to experience growth during the forecast period due to the rising prevalence of lupus nephritis, increasing awareness and adoption of approved therapies beyond off-label corticosteroids, continued innovation in targeted therapies and next-generation therapies (dual APRIL/BAFF Antagonist, BAFF-R inhibitor, complement inhibitor, CAR-T cell therapies, etc.), and launch of promising emerging therapies, including GAZYVA (obinutuzumab), SAPHNELO (anifrolumab), and Ianalumab, among others.
LAS VEGAS, Oct. 6, 2025 /PRNewswire/ -- DelveInsight's Lupus Nephritis Market Insights report includes a comprehensive understanding of current treatment practices, lupus nephritis emerging drugs, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].
Nenhum comentário